Dr. Reddy’s Laboratories Limited Updates Insider Trading Code
Dr. Reddy’s Laboratories Limited announced an amendment to its 'Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information' on March 24, 2026. The updated code is in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended.According to the updated code, “Un-published Price Sensitive Information” (UPSI) means information as defined under clause of regulation 2 (1) of the SEBI PIT Regulation. The Head of Investor Relations has been designated as Chief Investor Relations Officer.
The company will promptly furnish material information related to any UPSI to the National Stock Exchange of India Ltd. (Scrip Code: DRREDDY), BSE Limited (Scrip Code: 500124), New York Stock Exchange Inc. (Stock Code: RDY), and NSE IFSC Ltd. (Stock Code: DRREDDY). This information may also be hosted on the company's website.
The code mandates uniform and universal disclosure of UPSI, and prohibits the disclosure of UPSI through any social media platform. In the event of unintentional disclosure, the company will disseminate the information publicly within 24 hours.
The code defines “legitimate purpose” as including sharing of UPSI with partners, collaborators, lenders, customers, suppliers, merchant bankers, legal advisors, auditors, insolvency professionals or other advisors or consultants. Those with whom UPSI is shared will be considered insiders and required to maintain confidentiality.
Dr. Reddy's Laboratories Limited will maintain a digital database containing details of UPSI shared, including the names of individuals involved and their Permanent Account Numbers (PAN) or other legal identifiers. This database will be preserved for at least eight years.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.